Skip to content

Prevalence of Hepatitis B Infection in the Galilee Region, Israel

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01645007
Enrollment
0
Registered
2012-07-19
Start date
Unknown
Completion date
Unknown
Last updated
2014-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B

Keywords

Hepatitis B, Prevalence, HBsAg, Vaccination, Galilee

Brief summary

Primary Aims: 1. Evaluate HBV (Hepatitis B Virus) infection prevalence among Druze in the Galilee. 2. Educate the population in order to reduce transmission 3. Increase awareness among primary care providers Secondary Aims: 1. Identify chronic HBV infected patients who need to be followed and treated, 2. Identify HBV infected women in a childbearing age 3. Identify non immunized individuals and recommend vaccination 4. Identify previously vaccinated individuals who are not immunized 5. Identify previously vaccinated individuals who became infected Study Design: Study population is targeted to native Israeli Druze. We aim for evaluating up to 20,000 people from Druze communities in the Galilee area This work will be divided into three sections: 1. Increasing awareness: lectures and local events will be taken place in the communities. Written information will be given and primary care-providers mainly family doctors, nurses and obstetric surgeons will be involved. 2. All participants, upon signing a consent will: * Fill up a questioner * Checked for weight, height and waist circumflex * Have a blood sample taken 3. Results and recommendations will be forwarded to all participants

Interventions

None listed

Sponsors

Western Galilee Hospital-Nahariya
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* All consent adults who are 18 year old or older

Exclusion criteria

* Individuals younger than 18 year old * Individuals who cannot or will not sign consent

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026